Roger E. Susi Sells 10,000 Shares of IRadimed Co. (NASDAQ:IRMD) Stock

IRadimed Co. (NASDAQ:IRMDGet Rating) CEO Roger E. Susi sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $46.20, for a total value of $462,000.00. Following the completion of the transaction, the chief executive officer now owns 502,950 shares of the company’s stock, valued at $23,236,290. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

IRadimed Trading Up 1.5 %

Shares of IRadimed stock opened at $47.54 on Tuesday. The firm has a market capitalization of $599.00 million, a PE ratio of 43.61 and a beta of 1.06. IRadimed Co. has a twelve month low of $26.00 and a twelve month high of $47.88. The firm’s 50-day moving average price is $40.04 and its 200 day moving average price is $34.45.

IRadimed (NASDAQ:IRMDGet Rating) last announced its quarterly earnings data on Thursday, May 4th. The medical equipment provider reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The company had revenue of $15.48 million for the quarter, compared to analyst estimates of $14.76 million. IRadimed had a return on equity of 19.64% and a net margin of 24.27%. On average, sell-side analysts predict that IRadimed Co. will post 1.17 EPS for the current fiscal year.

Institutional Trading of IRadimed

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in shares of IRadimed by 51.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,131 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 384 shares during the period. James Investment Research Inc. purchased a new stake in IRadimed during the first quarter worth about $69,000. Advisor Group Holdings Inc. boosted its stake in shares of IRadimed by 82.3% in the first quarter. Advisor Group Holdings Inc. now owns 2,167 shares of the medical equipment provider’s stock valued at $98,000 after purchasing an additional 978 shares during the period. BNP Paribas Arbitrage SNC boosted its position in IRadimed by 107.3% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 3,615 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 1,871 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of IRadimed during the first quarter worth $117,000. Hedge funds and other institutional investors own 50.03% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. MKM Partners upped their price target on shares of IRadimed from $46.00 to $48.00 in a report on Monday, February 6th. lowered IRadimed from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, Lake Street Capital began coverage on shares of IRadimed in a research note on Wednesday, April 12th. They set a “buy” rating and a $50.00 target price on the stock.

IRadimed Company Profile

(Get Rating)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Read More

Insider Buying and Selling by Quarter for IRadimed (NASDAQ:IRMD)

Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with's FREE daily email newsletter.